| Clinical data | |
|---|---|
| Trade names | Befol(RU) |
| Other names | Befol |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H19ClN2O2 |
| Molar mass | 282.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Eprobemide (INN) is a pharmaceutical drug that was used as anantidepressant in Russia (under the brand nameБефол/Befol).[1] It is a non-competitivereversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs frommoclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |